Healthcare Equipment and Supplies
Company Overview of nContact, Inc.
nContact, Inc., a cardiac ablation device company, develops and manufactures medical devices for the minimally invasive treatment of heart arrhythmias in the United States. It develops Numeris coagulation system with VisiTrax, which is indicated for the coagulation of cardiac tissue; and Numeris guided coagulation system, which is used in closed chest procedures, as well as allows the coil end to be maneuvered along a guidewire, through the paracardioscopic cannula, to endoscopically create bi-atrial lesions. The company was formerly known as nContact Surgical, Inc. and changed its name to nContact, Inc. on January 10, 2011. The company was founded in 2005 and is headquartered in Morrisville...
1001 Aviation Parkway
Morrisville, NC 27560
Founded in 2005
Key Executives for nContact, Inc.
Co-Founder and Vice President of Research & Clinicals
Co-Founder and Vice President of Development & Operations
Vice President of Finance
Compensation as of Fiscal Year 2015.
nContact, Inc. Key Developments
nContact Appoints William Hawkins as Chairman of its Board of Directors
Jul 21 15
nContact announced that William (Bill) Hawkins has been appointed as Chairman of its Board of Directors. Bill Hawkins has served as a special advisor to the nContact Board since 2013 and is a veteran entrepreneur and executive in the medical device arena, with more than 20 years of C-Suite experience in cardiology, surgery, and vascular therapies. Most recently, Bill was President and CEO of Immucor.
nContact Secures $20 Million in Growth Capital Financing
Nov 12 14
nContact announced that it has entered into a $20 million growth capital financing agreement with Hercules Technology Growth Capital, Inc. The company plans to use this financing to support its ongoing CONVERGE IDE Clinical Trial, expand its field support teams, and further next-generation product development. The randomized CONVERGE IDE clinical trial is the first head-to-head study comparing the multidisciplinary Convergent Procedure to traditional catheter ablation in the treatment of persistent AF. AF is the most common arrhythmia, affecting 15 million people in the western world, with an estimated 88% falling into the difficult-to-treat persistent AF population. The CONVERGE clinical trial randomizes patients 2:1 between the epicardial-endocardial Convergent Procedure and endocardial-only ablation with fluid-irrigated catheters.
nContact, Inc. Announces First Patient Treated in the CONVERGE IDE Clinical Trial
Jan 8 14
nContact, Inc. announced the first patient treated in the CONVERGE IDE Clinical Trial, a multicenter, prospective, randomized study evaluating patients with symptomatic persistent atrial fibrillation (AF). AF is the most common cardiac arrhythmia, estimated to affect 5.9 million people in the U.S., with a majority of patients falling into the difficult-to-treat persistent AF population. The CONVERGE Study is designed to investigate the treatment of persistent AF patients with the multidisciplinary Convergent Procedure, an epicardial-endocardial approach that utilizes the collaborative expertise and techniques of an electrophysiologist and cardiothoracic surgeon. The multidisciplinary Convergent Procedure is performed as a single procedure in the electrophysiology lab. The epicardial lesions are created first under direct endoscopic visualization by a surgeon, through a 2 cm incision in the abdomen, with no chest incisions or ports. The endocardial lesions created by an electrophysiologist help confirm lesion set completeness through specialized EP diagnostics, which also predict outcomes.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 12, 2014